Riskpilot← Back to searchSign inGet full accessBiocrine AB
ABActiveOrg 5567277933Sveavägen 166 5trResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20078 employees
Revenue 2024
SEK 0
EBITDA margin
—
+8% vs 2023
Equity ratio
90.3%
Financial strength
Net profit 2024
SEK -9,1M
+7% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -9,1M | +8% |
| Net profit | SEK -9,1M | +7% |
| Total assets | SEK 14,1M | +6% |
| Equity | SEK 12,8M | +32% |
| Employees | 8 | — |
Legal name
Biocrine AB
Org number
5567277933
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4 april 2007
Share capital
SEK 297 000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna Firman tecknas ensam av externa firmatecknaren
Company purpose
Bolaget skall bedriva forskning och utveckling inom bioteknik- området, huvudsakligen inom diabeteselaterade sjukdomar, ävensom marknadsföring och försäljning av produkter och metoder och licensiering av immateriella rättigheter inom ovan nämnda område samt därmed förenlig verksamhet.
Address
Sveavägen 166 5tr
Phone
+46736151604
Email
info@biocrine.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −8 879 | −7 947 | −8 838 | −10 350 | −6 365 | −8 861 | −7 036 | −7 421 | −9 863 | −9 080 |
| Depreciation & amort. | −2 211 | −1 402 | −0 | −0 | −0 | −6 825 | −1 450 | −0 | −0 | −0 |
| EBIT | −11 090 | −9 349 | −8 838 | −10 350 | −6 365 | −15 686 | −8 486 | −7 421 | −9 863 | −9 080 |
| Net financials | −22 | −43 | −21 | −21 | −127 | 33 | −5 | −29 | 60 | −20 |
| Profit before tax | −11 112 | −9 392 | −8 859 | −10 370 | −6 491 | −15 653 | −8 492 | −7 449 | −9 803 | −9 100 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −11 112 | −9 392 | −8 859 | −10 370 | −6 491 | −15 653 | −8 492 | −7 449 | −9 803 | −9 100 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 20 430 | 28 116 | 19 391 | 17 680 | 22 042 | 21 902 | 13 633 | 21 103 | 13 295 | 14 145 |
| Equity | 20 018 | 27 627 | 18 767 | 14 202 | 20 912 | 21 410 | 12 918 | 19 469 | 9 665 | 12 770 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 412 | 489 | 624 | 3 478 | 1 129 | 492 | 715 | 1 634 | 3 629 | 1 375 |
| Total debt | 412 | 489 | 624 | 3 478 | 1 129 | 492 | 715 | 1 634 | 3 629 | 1 375 |
EBITDA margin
-908000000.0%
This company
15.8%
Market median
-5746835543% vs market
20152024
Equity ratio
90.3%
This company
38.2%
Market median
+136% vs market
20152024
Return on equity
-71.3%
This company
18.4%
Market median
-488% vs market
20152024
Net profit margin
-910000000.0%
This company
8.1%
Market median
-11234568001% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PL Audit | Audit | 2022 | — | — |
UP Audit | Audit | 2022 | — | — |
IC External Signatory | External Signatory | 2024 | — | — |
YP Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Biocrine AB 
Biocrine Regenerative Medicine AktiebolagBoard members of Biocrine AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pia Linda Johansson | Audit | 0 companies |
| Ulf Peter Burholm | Audit | 0 companies |
| Ingrid Catharina Liljeryd | External Signatory | 0 companies |
| Yngve Per-Olof Berggren | Chief Executive Officer | 0 companies |
| Bertil Henry Herbert Andersson | Board of Directors | 0 companies |
| Claes-Henrik Julander | Board of Directors | 0 companies |
| Kenth Ingemar Petersson | Chairman | 0 companies |